1 / 4

Biosimilar of Remicade

The global biosimilar of remicade market size increased significantly in 2020 and is expected to register double-digit revenue CAGR

rucha4
Download Presentation

Biosimilar of Remicade

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Biosimilars of Remicade: A Brief Overview

  2. Brief about Biosimilar of Remicade? • One example of a biosimilar to Remicade is Inflectra (infliximab-dyyb), which was approved by the U.S. Food and Drug Administration (FDA) in 2016. Another biosimilar is Renflexis (infliximab-abda), which received FDA approval in 2017. • These biosimilars are designed to be highly similar to Remicade in terms of safety and efficacy, and they undergo rigorous testing to demonstrate their comparability to the reference product. Biosimilars are intended to provide more affordable alternatives to the originator biologic while maintaining a similar therapeutic effect.

  3. Market Summary: The global biosimilar of remicade market size increased significantly in 2020 and is expected to register double-digit revenue CAGR over the forecast period. Major factors driving market revenue growth include global change in trend toward bio-based products. Another major factor driving market growth is early patent exclusivity loss. Get more information: https://www.reportsanddata.com/download-free-sample/4029

  4. Thank You!!!

More Related